Torii Pharmaceutical Co., Ltd. (4551.T)
JPY 4440.0
(0.57%)
JPY 4440.0
(0.57%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 244 Million JPY | -53.44% |
| 2022 | 524 Million JPY | 7.82% |
| 2021 | 486 Million JPY | 65.31% |
| 2020 | 294 Million JPY | -22.43% |
| 2019 | 379 Million JPY | -18.49% |
| 2018 | 465 Million JPY | -15.45% |
| 2017 | 550 Million JPY | -28.57% |
| 2016 | 770 Million JPY | -27.84% |
| 2015 | 1.06 Billion JPY | 48.61% |
| 2014 | 718 Million JPY | 82.23% |
| 2013 | 394 Million JPY | 86.73% |
| 2012 | 211 Million JPY | 486.11% |
| 2011 | 36 Million JPY | -32.08% |
| 2010 | 53 Million JPY | 6.0% |
| 2009 | 50 Million JPY | -60.94% |
| 2008 | 128 Million JPY | 0.0% |
| 2007 | - JPY | 0.0% |
| 2006 | - JPY | 0.0% |
| 2005 | - JPY | 0.0% |
| 2004 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 299 Million JPY | 22.54% |
| 2024 Q2 | 302 Million JPY | 1.0% |
| 2024 Q3 | - JPY | 98.34% |
| 2023 Q4 | 244 Million JPY | -29.89% |
| 2023 Q1 | 464 Million JPY | -11.45% |
| 2023 Q3 | 348 Million JPY | -12.56% |
| 2023 FY | 244 Million JPY | -53.44% |
| 2023 Q2 | 398 Million JPY | -14.22% |
| 2022 Q2 | 678 Million JPY | -9.48% |
| 2022 Q4 | 524 Million JPY | -13.39% |
| 2022 FY | 524 Million JPY | 7.82% |
| 2022 Q1 | 749 Million JPY | 54.12% |
| 2022 Q3 | 605 Million JPY | -10.77% |
| 2021 Q4 | 486 Million JPY | 6.81% |
| 2021 FY | 486 Million JPY | 65.31% |
| 2021 Q1 | 501 Million JPY | 70.41% |
| 2021 Q2 | 484 Million JPY | -3.39% |
| 2021 Q3 | 455 Million JPY | -5.99% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 FY | 294 Million JPY | -22.43% |
| 2020 Q4 | 294 Million JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2019 Q4 | 379 Million JPY | 0.0% |
| 2019 FY | 379 Million JPY | -18.49% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q1 | - JPY | -100.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2018 Q4 | 465 Million JPY | 0.0% |
| 2018 FY | 465 Million JPY | -15.45% |
| 2018 Q1 | - JPY | -100.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2017 Q4 | 550 Million JPY | 0.0% |
| 2017 Q2 | - JPY | 0.0% |
| 2017 Q1 | - JPY | -100.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2017 FY | 550 Million JPY | -28.57% |
| 2016 Q3 | - JPY | 0.0% |
| 2016 FY | 770 Million JPY | -27.84% |
| 2016 Q2 | - JPY | 0.0% |
| 2016 Q4 | 770 Million JPY | 0.0% |
| 2016 Q1 | - JPY | -100.0% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 Q3 | - JPY | 0.0% |
| 2015 Q1 | - JPY | 0.0% |
| 2015 FY | 1.06 Billion JPY | 48.61% |
| 2015 Q4 | 1.06 Billion JPY | 0.0% |
| 2014 Q1 | 394 Million JPY | 0.0% |
| 2014 FY | 718 Million JPY | 82.23% |
| 2014 Q3 | - JPY | 0.0% |
| 2014 Q2 | - JPY | -100.0% |
| 2013 Q4 | - JPY | 0.0% |
| 2013 Q1 | 211 Million JPY | 0.0% |
| 2013 Q2 | - JPY | -100.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 FY | 394 Million JPY | 86.73% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 FY | 211 Million JPY | 486.11% |
| 2012 Q4 | - JPY | 0.0% |
| 2012 Q2 | - JPY | -100.0% |
| 2012 Q1 | 36 Million JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 FY | 36 Million JPY | -32.08% |
| 2011 Q1 | 53 Million JPY | 0.0% |
| 2011 Q2 | - JPY | -100.0% |
| 2011 Q4 | - JPY | 0.0% |
| 2010 Q1 | 50 Million JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 FY | 53 Million JPY | 6.0% |
| 2010 Q2 | - JPY | -100.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | 50 Million JPY | -60.94% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q1 | 128 Million JPY | 0.0% |
| 2008 FY | 128 Million JPY | 0.0% |
| 2008 Q4 | - JPY | 0.0% |
| 2007 FY | - JPY | 0.0% |
| 2006 FY | - JPY | 0.0% |
| 2005 FY | - JPY | 0.0% |
| 2004 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 16.89 Billion JPY | 98.555% |
| Takeda Pharmaceutical Company Limited | 4843.75 Billion JPY | 99.995% |
| Sumitomo Pharma Co., Ltd. | 418.88 Billion JPY | 99.942% |
| Shionogi & Co., Ltd. | 11.62 Billion JPY | 97.9% |
| Wakamoto Pharmaceutical Co.,Ltd. | 100.52 Million JPY | -142.716% |
| Nippon Shinyaku Co., Ltd. | 2.87 Billion JPY | 91.504% |
| Kaken Pharmaceutical Co., Ltd. | 3.85 Billion JPY | 93.662% |
| Eisai Co., Ltd. | 206.74 Billion JPY | 99.882% |
| Morishita Jintan Co., Ltd. | 425 Million JPY | 42.588% |
| Hisamitsu Pharmaceutical Co., Inc. | 2.1 Billion JPY | 88.381% |
| Mochida Pharmaceutical Co., Ltd. | 369 Million JPY | 33.875% |
| Fuso Pharmaceutical Industries,Ltd. | 12.72 Billion JPY | 98.082% |
| Nippon Chemiphar Co., Ltd. | 16.98 Billion JPY | 98.563% |
| Tsumura & Co. | 79.69 Billion JPY | 99.694% |
| Kissei Pharmaceutical Co., Ltd. | 1.72 Billion JPY | 85.871% |
| Towa Pharmaceutical Co., Ltd. | 202.35 Billion JPY | 99.879% |
| Fuji Pharma Co., Ltd. | 28.94 Billion JPY | 99.157% |
| Zeria Pharmaceutical Co., Ltd. | 47.58 Billion JPY | 99.487% |
| KYORIN Holdings, Inc. | 20.94 Billion JPY | 98.835% |
| Taiko Pharmaceutical Co.,Ltd. | 3.8 Billion JPY | 93.594% |
| Daito Pharmaceutical Co.,Ltd. | 8.71 Billion JPY | 97.202% |
| SymBio Pharmaceuticals Limited | - JPY | -Infinity% |
| MedRx Co., Ltd | - JPY | -Infinity% |
| Mizuho Medy Co.,Ltd. | - JPY | -Infinity% |
| Solasia Pharma K.K. | 60 Million JPY | -306.667% |
| Modalis Therapeutics Corporation | 412.5 Million JPY | 40.848% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.48 Billion JPY | 97.428% |
| Sawai Group Holdings Co., Ltd. | 82.89 Billion JPY | 99.706% |
| Cyfuse Biomedical K.K. | 913 Million JPY | 73.275% |
| Toho Holdings Co., Ltd. | 30.24 Billion JPY | 99.193% |
| Koa Shoji Holdings Co.,Ltd. | 2.82 Billion JPY | 91.364% |